My Cart

0 Item(s): $0.00

You have no items in your shopping cart.

Sofosbuvir & Velpatasvir

Sofosbuvir & Velpatasvir

Why is this medication prescribed?

The combination of sofosbuvir and velpatasvir is used alone or with ribavirin (Copegus, Rebetol, Ribasphere) to treat chronic hepatitis C (an ongoing viral infection that damages the liver). Sofosbuvir is in a class of antiviral medications called nucleotide hepatitis C virus (HCV) NS5B polymerase inhibitors. Velpatasvir is in a class of antiviral medications called HCV NS5A replication complex inhibitors. The combination of sofosbuvir and velpatasvir works by stopping the virus that causes hepatitis C from spreading inside the body.

Class And Mechanism

Sofosbuvir-Velpatasvir (Epclusa) is an oral fixed-dose combination of sofosbuvir, a nucleotide analog NS5B polymerase inhibitor and velapatasvir, an NS5A replication complex inhibitor. Sofosbuvir is currently approved in the United States for the treatment of genotype 1, 2, 3 and 4 HCV infection with different regimens and durations dependent on the HCV genotype. Velpatasvir (formerly GS-5816) is a novel NS5A inhibitor that has potent in vitro anti-HCV activity across all genotypes at the picomolar level. The combination of sofosbuvir-velpatasvir is the first once-daily single-tablet regimen with pangenotypic activity.

What side effects can this medication cause?

  • rash
  • lack of energy
  • feeling irritable
  • feeling depressed

Uses

This medication is a combination of sofosbuvir and velpatasvir and is used to treat chronic (long-lasting) hepatitis C, a viral infection of the liver. It may sometimes be used with another antiviral medication (ribavirin). These drugs work by reducing the amount of hepatitis C virus in your body, which helps your immune system fight the infection and may help your liver recover. Chronic hepatitis C infection can cause serious liver problems such as scarring (cirrhosis), or liver cancer.

Dosage Forms & Strengths

sofosbuvir/velpatasvir

tablet

  • 400mg/100mg

Pregnancy

Contraindicated if administered with ribavirin in pregnant women and in men whose female partners are pregnant

There are no adequate data available to establish pregnancy risk for sofosbuvir or velpatasvir

Lactation

Unknown if sofosbuvir, velpatasvir, or their metabolites are distributed in human breast milk

Consider the developmental and health benefits of breastfeeding along with the mother’s clinical need for the drug, and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition

If regimen includes ribavirin, refer to ribavirin prescribing information

Loading...